Odonate Therapeutics
 
 

OUR COMPANY

We are a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Our initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Tesetaxel has several pharmacologic properties that make it unique among taxanes, including: oral administration with a low pill burden; a long (~8-day) terminal plasma half-life ("t1/2") in humans, enabling the maintenance of adequate drug levels with relatively infrequent dosing; no history of hypersensitivity (allergic) reactions; and significant activity against chemotherapy-resistant tumors. More than 500 patients have been treated with tesetaxel in clinical studies. In patients with metastatic breast cancer (“MBC”), tesetaxel was shown to have significant, single-agent antitumor activity in two multicenter, Phase 2 studies. In December 2017, Odonate initiated CONTESSA, a multinational, multicenter, randomized, Phase 3 study of tesetaxel in patients with locally advanced or metastatic breast cancer ("LA/MBC") (clinicaltrials.gov). Our goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.

OUR NAME

odo·nate
\ˈō-də-ˌnāt, ō-ˈdä-(ˌ)nāt\

n. (Zoology) an insect, such as a dragonfly, that belongs to the zoological group Odonata

Dragonfly Symbolism
“The dragonfly’s agile flight and its ability to move in all six directions exude a sense of power and poise - something that comes only with age and maturity...The awe inspiring aspect is how the dragonfly accomplishes its objectives with utmost simplicity, effectiveness and well, if you look at proportions, with 20 times as much power in each of its wing strokes when compared to the other insects. The best part is that the dragonfly does it with elegance and grace that can be compared to a veteran ballet dancer.” 
 
 

OUR VALUES

Focus on the Patient
We are dedicated to improving the lives of patients in need
Operate with Integrity
Our word is our most valuable asset
Bring Passion
We take pride in our work and strive for excellence in all that we do
Be Creative
The best way is often yet to be discovered
Foster Unity
We are one community
Be Kind
We believe in the inherent goodness of people and strive to treat everyone with kindness
Promote Equal Opportunity
Every person should be offered an opportunity to achieve success in all aspects of life
Give Forward
We receive happiness from helping those in need within our local and global community
Find Joy
We support personal goals for physical, mental and spiritual well-being
 

BOARD OF DIRECTORS

Kevin Tang
Chairman and Chief Executive Officer
Aaron Davis
Director
Craig Johnson
Director
Laura Johnson Douglass
Director
Robert Rosen
Director
 

Kevin Tang

Chairman and Chief Executive Officer

 

Mr. Tang has served as our Chairman and Chief Executive Officer since the Company’s inception in 2013. Mr. Tang also serves as President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002 and an affiliate of the Company. Since 2014, Mr. Tang has served as a director and Chairman of La Jolla Pharmaceutical Company. Since 2009, Mr. Tang has served as a director of Heron Therapeutics, Inc. and, since 2012, has served as Chairman. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, he served as a director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, he was a director of Trimeris, Inc. From 1993 to 2001, Mr. Tang held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.

 

 

Aaron Davis

Director

 

Mr. Davis has served as a director since 2016. Mr. Davis has been the Chief Executive Officer of Boxer Capital, the healthcare arm of Tavistock Group, since 2012. Mr. Davis co-founded Boxer Capital in 2005 and, prior to being appointed Chief Executive Officer, served as Portfolio Manager. Since 2016, Mr. Davis has served as a director of CiVi Biopharma, Inc. From 2006 to 2008, he served as a director of Kalypsys, Inc. From 2000 to 2004, Mr. Davis worked in the Global Healthcare Investment Banking and Private Equity Group at UBS Warburg, LLC. Mr. Davis received an M.A. degree in biotechnology from Columbia University and a B.B.A. degree in finance from Emory University.

 

 

Craig Johnson

Director

 

Mr. Johnson has served as a director since July 2017. Mr. Johnson also is a director of Heron Therapeutics, Inc., La Jolla Pharmaceutical Company and Mirati Therapeutics, Inc. Mr. Johnson also served as a director of GenomeDx Biosciences, Inc. from 2015 to 2018. Mr. Johnson also served as a director of Ardea Biosciences, Inc. from 2008 until its acquisition by AstraZeneca PLC in 2012, and as a director of Adamis Pharmaceuticals Corporation from 2011 to 2014. From 2011 to 2012, he served as Chief Financial Officer of PURE Bioscience, Inc., and, from 2010 to 2011, Mr. Johnson served as Senior Vice President and Chief Financial Officer of NovaDel Pharma Inc. From 2004 through its acquisition by Raptor Pharmaceuticals Corp. in 2009, he served as Vice President and Chief Financial Officer of TorreyPines Therapeutics, Inc., and, from 2009 to 2010, as Vice President of a wholly-owned subsidiary of Raptor Pharmaceuticals Corp. From 1994 to 2004, Mr. Johnson held various positions at MitoKor, Inc., most recently serving as Chief Financial Officer and Senior Vice President of Operations. Mr. Johnson received a B.B.A. degree in accounting from the University of Michigan-Dearborn.

 

 

Laura Johnson Douglass

Director

 

Ms. Douglass has served as a director since December 2018. Ms. Douglass is the President and Chief Executive Officer of Next Generation Clinical Research Consulting, Inc., a contract research organization servicing the pharmaceutical industry that she founded in 1999. Additionally, Ms. Douglass is the President and Chief Executive Officer for Eufaeria Biosciences, Inc., a biotechnology company that she founded in 2016. Ms. Douglass is a director of La Jolla Pharmaceutical Company. Ms. Douglass is also a founder and director of Sb Bancorp, Inc. and Settlers Bank, Inc. Ms. Douglass received a nursing degree from The University of the State of New York-Albany.

 

 

Robert Rosen

Director

 

Mr. Rosen has served as a director since July 2017. From 2013 to February 2019, Mr. Rosen served as President and as a director of Heron Therapeutics, Inc., and, from 2012 to 2013, served as Senior Vice President and Chief Commercial Officer of Heron Therapeutics, Inc. Since 2014, he has served as a director of La Jolla Pharmaceutical Company. From 2014 to 2015, Mr. Rosen served as a director of Conkwest, Inc. (now NantKwest, Inc.). In 2012, he served as Managing Partner of Scotia Nordic LLC, a life sciences advisory firm. From 2011 to 2012, Mr. Rosen served as Senior Vice President of Global Commercial Operations at Dendreon Corporation. From 2005 to 2011, he served as Global Head of Oncology at Bayer HealthCare Pharmaceuticals. From 2002 to 2005, Mr. Rosen was Vice President of the Oncology Business Unit at Sanofi-Synthèlabo Inc. Mr. Rosen received a B.S. degree in pharmacy from Northeastern University.

 
 
 
 
 

MANAGEMENT

Kevin Tang
Chairman and Chief Executive Officer
 
Stew Kroll
Chief Development Officer
 
John Lemkey
Chief Operating Officer
 
Joseph O’Connell, M.D.

Chief Medical Officer

 
Thomas Wei
Chief Scientific Officer
 
Michael Hearne
Chief Financial Officer
 
Natasha Bartasch-Price
Vice President of Regulatory Operations
 
Ryan Cole
Vice President of Operations
 
Jill Krause
Vice President of Clinical Training
Kim Ma
Vice President of Clinical Operations
Tracey McKennon
Vice President of Quality Assurance
 
Steven Pfeiffer, Ph.D.
Vice President of Technical Operations
 
Jennifer Schroeder
Vice President of Program Management and Technology
 
 
Kevin Tang

Chairman and Chief Executive Officer

 

Mr. Tang has served as our Chairman and Chief Executive Officer since the Company’s inception in 2013. Mr. Tang also serves as President of Tang Capital Management, LLC, a life sciences-focused investment company he founded in 2002 and an affiliate of the Company. Since 2014, Mr. Tang has served as a director and Chairman of La Jolla Pharmaceutical Company. Since 2009, Mr. Tang has served as a director of Heron Therapeutics, Inc. and, since 2012, has served as Chairman. From 2009 through its acquisition by Endo Pharmaceuticals, Inc. in 2010, he served as a director of Penwest Pharmaceuticals Co. In 2006, Mr. Tang co-founded Ardea Biosciences, Inc. and served as a director from inception through its acquisition by AstraZeneca PLC in 2012. From 2001 to 2008, he was a director of Trimeris, Inc. From 1993 to 2001, Mr. Tang held various positions at Deutsche Banc Alex Brown, Inc., an investment banking firm, most recently serving as Managing Director and head of the firm’s Life Sciences research group. Mr. Tang received a B.S. degree from Duke University.

 

 

Stew Kroll

Chief Development Officer

 

Mr. Kroll has served as our Chief Development Officer since November 2018 and previously held various positions, most recently serving as Senior Vice President of Biometrics and Regulatory Strategy, from 2016 to 2018. From 2005 to 2016, Mr. Kroll held various positions at Threshold Pharmaceuticals, Inc., most recently serving as Chief Operating Officer. From 2000 to 2005, he served as Senior Director of Biostatistics at Corixa Corporation. From 1997 to 2000, Mr. Kroll held various positions at Coulter Pharmaceutical, Inc., most recently serving as Director of Biostatistics. Mr. Kroll received an M.A. degree and B.A. degree in statistics from the University of California, Berkeley.

 

 

John Lemkey

Chief Operating Officer

 

Mr. Lemkey has served as our Chief Operating Officer since November 2018 and previously as Chief Financial Officer from 2013 to 2018. Since 2012, Mr. Lemkey has served as Chief Operating Officer of Tang Capital Management, LLC, a life sciences-focused investment company and an affiliate of the Company, which Mr. Lemkey joined in 2006. From 2003 to 2006, Mr. Lemkey was a Senior Auditor at Ernst & Young LLP. Mr. Lemkey received a B.S. degree in accounting from the University of Southern California and is a Certified Public Accountant (inactive) in the state of California.

 

 

Joseph O'Connell, M.D.

Chief Medical Officer

 

Dr. O’Connell has served as our Chief Medical Officer since September 2017. From 2015 to 2017, Dr. O’Connell served as Vice President, Medical and Scientific Affairs, Hematology and Oncology at inVentiv Health Clinical, LLC. From 2007 to 2015, Dr. O’Connell held various positions at Pfizer Inc., most recently serving as Senior Director and Asset Global Clinical Lead for Oncology. Prior to 2007, he practiced adult medical oncology for more than 15 years, including at the Yale Cancer Center. Dr. O’Connell received a B.S. degree in biology from Fordham University and an M.D. degree from the State University of New York, and completed his Oncology Fellowship at Memorial Sloan Kettering Cancer Center.

 

Thomas Wei

Chief Scientific Officer

 

Mr. Wei has served as our Chief Scientific Officer since November 2018 and previously as our Senior Vice President of Research and Development from 2015 to 2018. Mr. Wei also is Managing Director at Tang Capital Management, LLC, a life sciences-focused investment company and an affiliate of the Company, which he joined in 2015. From 2009 to 2015, he served as a Managing Director and biotechnology equity research analyst at Jefferies LLC. From 2003 to 2009, Mr. Wei was a biotechnology equity research analyst at Piper Jaffray, most recently serving as Managing Director. From 1998 to 2003, Mr. Wei was a biotechnology equity research analyst at Deutsche Bank AG and Adams, Harkness & Hill Inc. Mr. Wei received an A.B. degree in biochemical sciences from Harvard University and an M.B.A. degree from Oxford University.

 

Michael Hearne

Chief Financial Officer

 

Mr. Hearne has served as our Chief Financial Officer since November 2018 and previously as Vice President of Finance and Accounting from 2015 to 2018. Since 2015, Mr. Hearne has also served as Chief Financial Officer of Tang Capital Management, LLC, a life sciences-focused investment company and an affiliate of the Company. From 2014 to 2015, Mr. Hearne served as a Partner at Weaver & Tidwell, LLP. From 2008 to 2014, Mr. Hearne had his own financial consulting business. From 2000 to 2008, Mr. Hearne served as a Partner at Rothstein Kass & Company, P.C. Mr. Hearne started his public accounting career at Coopers & Lybrand in 1988. Mr. Hearne received a B.S. degree in accounting and a Masters of Accountancy, Taxation from Brigham Young University and is a Certified Public Accountant (inactive) in the state of California.

 

 

Natasha Bartasch-Price

Vice President of Regulatory Operations

 

Ms. Bartasch-Price has served as our Vice President of Regulatory Operations since July 2018 and previously as our Vice President of Program Management from October 2017 to July 2018. From 2016 to 2017, Ms. Bartasch-Price served as Vice President, Global Project Management and Managing Director, Patient Recruitment and Retention at Bioclinica, Inc. From 2000 to 2016, Ms. Bartasch-Price held various positions at Pfizer Inc., most recently serving as Senior Director, Clinical Operations Program Lead. Ms. Bartasch-Price received a B.S. degree in biology from Shippensburg University and an M.B.A. degree from Eastern University.

 

 

 

Ryan Cole

Vice President of Operations

 

Mr. Cole has served as our Vice President of Operations since December 2017 and previously held various positions, most recently serving as Senior Director of Operations, from 2014 to 2017. From 2012 to 2014, Mr. Cole was a Senior Financial Analyst, Mergers and Acquisitions at Thermo Fisher Scientific Inc. From 2009 to 2012, he was a Senior Auditor at Ernst & Young LLP. Mr. Cole received a B.S. degree in accounting from Santa Clara University and is a Certified Public Accountant (inactive) in the state of California. 

 

 

Jill Krause

Vice President of Clinical Training

 

Ms. Krause has served as our Vice President of Clinical Training since July 2019 and previously held various positions, most recently serving as Vice President of Medical Affairs, from February 2019 to July 2019. From 1999 to 2017, Ms. Krause held various positions at Pfizer Inc., most recently serving as Director and Clinical Operations Program Lead. Ms. Krause received a B.S. degree in business administration and an M.B.A. degree from Eastern Michigan University.

Kim Ma

Vice President of Clinical Operations

 

Ms. Ma has served as our Vice President of Clinical Operations since February 2019 and previously held various positions, most recently serving as Senior Director of Clinical Operations, Head of Study Start-up, from June 2017 to February 2019. From 2014 to 2017, Ms. Ma held various positions at Pfizer Inc., most recently serving as Director in Clinical Project Management. From 2011 to 2014, Ms. Ma was a Senior Project Manager for the Pfizer Strategic Business Unit at ICON PLC and from 2008 to 2011, a Clinical Project Manager at Medtronic Diabetes. Ms. Ma received a B.S. degree in Biomedical Engineering from the University of Southern California and a M.S. degree in Regulatory Science from the University of Southern California School of Pharmacy.

Tracey McKennon

Vice President of Quality Assurance

 

Ms. McKennon has served as our Vice President of Quality Assurance since July 2018. From 2004 to 2018, Ms. McKennon held various positions at Seattle Genetics, Inc., most recently serving as Executive Director, Quality Assurance. From 1998 to 2004, she held various positions at Chiron Corporation, most recently as a Contract Manufacturing Manager. From 1996 to 1998, Ms. McKennon was a research associate at Eli Lilly and Company. Ms. McKennon received a B.S. degree in forensic and analytical chemistry from the University of Strathclyde and a M.S. degree in organic chemistry from Colorado State University.

 

 

Steven Pfeiffer, Ph.D.

Vice President of Technical Operations

 

Dr. Pfeiffer has served as our Vice President of Technical Operations since 2016. From 2015 to 2016, Dr. Pfeiffer was at Horizon Pharma PLC, most recently serving as Senior Director of Manufacturing and Development. From 2011 to 2015, he held various positions at Kythera Biopharmaceuticals, Inc., most recently serving as Associate Director of Product Research, Development and Manufacturing. From 2009 to 2010, Dr. Pfeiffer served as Associate Director at Sai Advantium Pharma Limited. From 2005 to 2009, he held various positions at Gilead Sciences, Inc., most recently serving as a Research Scientist II. Dr. Pfeiffer received a Ph.D. degree in chemistry from the University of California, Santa Barbara, an M.B.A. degree from California State University, East Bay, and a B.S. degree in chemistry from the University of Arizona.

 

 

Jennifer Schroeder

Vice President of Program Management and Technology

 

Ms. Schroeder has served as our Vice President of Program Management and Technology since February 2019 and previously as Vice President of Clinical Systems and Infrastructure from January 2018 to February 2019. From 1998 to 2018, Ms. Schroeder held various positions at Pfizer Inc., most recently serving as Senior Director, Head of Strategic Initiatives in Global Product Development. Ms. Schroeder received a B.S. degree in English from Eastern Michigan University and an M.A. degree in English from the University of Toledo.

 
 
 
 
 
 
 
 
 
 
 
 
 

Contact Us          Careers          Privacy Policy          Terms of Use

© 2019 Odonate Therapeutics, Inc.